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Abstract The association of aplastic anemia (AA) with
other autoimmune diseases (AID) has been described but
so far not systematically evaluated. We assessed the
incidence and the outcome of concomitant AID in a
retrospective, single-center study of 243 patients with
severe AA treated between 1974 and 2006 with either
immunosuppression (186) or hematopoietic stem cell
transplantation (57) and a median follow-up time of
9.3 years (0–33). Clinically manifest AID were observed
in 24 out of 243 (10±3.7%) patients. Age at diagnosis of
AA was significantly younger in patients without AID
compared to patients with AID (median, 20 versus
52 years; P<0.001). In 12 patients where the diagnosis
of AID was done before AA therapy, response to
antithymocyte globulin was good for AA (ten out of 12)
but not for AID (2 out of 12). In 13 patients in which AID
occurred after first-line therapy, the median time to the
AID was 7 years (range 3 months–27.5 years).
Keywords Aplastic anemia . Autoimmune diseases .
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Introduction
Aplastic anemia (AA) is defined as a pancytopenia with
unexplained bone marrow hypocellularity. Acquired AA
can be considered in most cases as a T cell-mediated
autoimmune disorder, targeted against the hematopoietic
progenitors, leading to the failure of the bone marrow [1].
Viral infections, drugs, chemical exposure, pregnancy, or
unknown agents seem to trigger the autoimmune dysregu-
lation in patients with predisposition. Associations of AA
and other autoimmune diseases (AID) have been shown in
single case reports [2, 3]. However, so far, there are no
published data on a systematic review of concomitant AID
in AA patients. Moreover, data on the impact of immuno-
suppressive strategies to treat AA, e.g., antithymocyte
globulin (ATG) and cyclosporine A (CSA) on the outcome
of AID, are scarce [4].
We sought to determine the incidence and characteristics
of concomitant AID diagnosed before or during the course
of AA and to compare AA patients with and without AID.
Materials and methods
This single-center, retrospective cohort study included all
243 patients with the diagnosis of AA, treated at the
University Hospital Basel, between 1974 and 2006. The
severity of AA was defined according to the widely
accepted criteria described by Camitta [5]. The general
treatment strategy was uniform with only minor changes
throughout the observation period. Patients younger than
40 years with a matched sibling donor received hemato-
poietic stem cell transplantation (HSCT) as first-line
therapy. Older patients and without an eligible sibling
donor were treated with intensive immunosuppression
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containing ATG [6] with or without CSA. Since 2001,
patients allocated to immunosuppression were included in
the prospective European study and randomized to receive
ATG and CSA with or without granulocyte colony-
stimulating factor [7]. In order to circumvent serum
sickness of ATG, most patients received steroids during
the early phase of the treatment. Patients with relapse or
nonresponse (NR) at 3 months usually were splenectomized
[8] and, if necessary, retreated with a second course of ATG
[9]. Response of AA to therapy was defined according to
the Camitta criteria [10]: Splenectomy was performed in
nonresponder patients before second-line therapy.
Concomitant AID were defined according to interna-
tional diagnostic criteria [11–17]. We retained in this study
only clinically evident AID. Isolated positive antibody
titers without further clinical signs were not included.
Response criteria for the concomitant AID were those
used for patients with autoimmune disorders treated with
HSCT, e.g., absence of all clinical signs without additional
therapy and normalization of laboratory values [18].
Patients were controlled yearly; clinical outcome data
were collected prospectively and stored in our local
database. To identify AID, medical records were system-
atically reviewed. This study was approved by local
Institutional Review Boards.
Statistical analysis
Left-truncated Cox models were used to assess the impact
of patients’ characteristics (gender, presence of HLA-DR2,
severity of AA, type of AA treatment [ATG, HSCT],
splenectomy) on the probability of developing an AID.
Severity of AA, AA treatment, and splenectomy were
coded as time-dependent covariates. Similarly, the impact
of development of AID on survival was assessed by coding
AID as a time-dependent risk factor in a Cox model. P
values <0.05 were considered significant.
Results
Of the 243 patients, there were 115 (47%) females. The
median age at diagnosis was 20 years (range 1–80 years),
the median follow-up time was 9.3 years (0–33). Very
severe AA was diagnosed in 128 (53%) patients and severe
AA in 115 (47%). Splenectomy was performed in 89 (37%)
patients. First-line therapy was ATG in 186 (77%) patients
and HSCT in 57 (23%) (Table 1). In 24 out of 243 (10%)
AA patients, a concomitant AID was diagnosed. Thirteen of
the patients (54%) had an AID before diagnosis of AA, and
11 (46%) after therapy for AA. Four out of these 24 patients
had more than one AID. In two of them, the first AID was
diagnosed before AA appearance and a second AID after
first-line therapy. We identified 16 different types of AID
(Table 2). The most frequent AID were autoimmune
gastritis (six patients) and autoimmune thyroiditis (six
patients). The median age at diagnosis of AA was
significant lower for patients without AID than patients
with a concomitant AID (20 versus 52 years; P<0.001)
(Fig. 1a, b). In our cohort, the cumulative incidence
according to the age of the patients at diagnosis of AA
increases mainly during the first three decades of age. In
Table 1 Pretreatment patients’ characteristics comparing patients with and without concomitant AID
All patients Without AID With AID P value
Number of patients, n (%) 243 219 (90) 24 (10)
Median age at diagnosis, years (range) 20 (1–80) 20 (1–80) 51.5 (9–75) <0.001a
Median follow-up, years (range) 9.3 (0–33) 9.3 (0–33) 11.5 (0–32) 0.219a
Sex, n (%)
Female 115 (47) 106 (46) 9 (38) 0.310b
Male 128 (53) 113 (54) 15 (62)
Severity, n (%)
Severe AA 115(47) 101 (46) 14 (58) 0.255b
Very severe AA 128 (53) 118 (54) 10 (42)
Splenectomy, n (%) 89 (37) 81 (37) 8 (33) 0.723b
HLA DRB1*15 present, n (%) 32 (49) (n=65) 21 (47) (n=45) 11 (55) (n=20) 0.598b
First-line treatment, n (%)
ATG 186 (77) 164 (75) 22 (92) 0.019b
HSCT 57 (23) 55 (25) 2 (8)
Need for a second-line treatment, n (%) 68 (28) 63 (29) 5 (21) 0.441b
aMann–Whitney U test
b Chi-square according to Pearson
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contrast, the cumulative incidence of AA patients with
concomitant AID increases predominantly after the fifth
decade of life (Fig. 1c).
In multivariate analysis comparing patients with and
without AID, there were no differences with respect to
gender (hazard ratio [HR]=0.540; 95%CI=0.232–1.260;
P=0.154), severity of the disease (HR=1.343; 95%CI=
0.503–3.588; P=0.556), presence of HLA-DRB1*15 (HR=
0.731; 95%CI=0.297–1.796; P=0.494), type of treatment
(HR=0.994; 95%CI=0.406–2.434; P=0.990), and splenec-
tomy (HR=0.987; 95%CI=0.214–4.547; P=0.987).
We evaluated the influence of the AA treatment on the
outcome of the concomitant AID in the 12 patients
where the AID appeared before the diagnosis of AA (one
patient was not included because Guillain–Barré syn-
drome resolved before ATG therapy). Five patients
obtained complete response (CR=41.5%) of the AA,
five obtained partial response (PR=41.5%), and two
were nonresponders (NR=17%). Complete response of
both diseases (AA and AID) was observed only in two
out of 12 (17%) patients. One patient presented an
eosinophilic fasciitis and the other a chronic juvenile
polyarthritis. In the other ten patients, the course of the
AID was not changed by the treatment of AA.
In 13 patients, the AID occurred after first-line therapy
for AA (11 patients, ATG; two patients, HSCT); we
evaluated the influence of this treatment on the develop-
ment of the concomitant AID. Two out of 13 patients had
had a first AID before diagnosis and therapy for AA. The
median time from ATG treatment to diagnosis of the first
AID was 7 years (range 3 months–27.5 years). At onset of
the AID, the AA was in CR in seven patients and in PR in
three patients. In two patients, there was NR and in one
patient, the type of response was unknown. After
allogeneic HSCT, two patients developed an AID. One
patient with graft rejection and subsequent autologous
reconstitution developed Graves’ disease 2 years later. He
is now in CR of the AA since more than three decades. A
second patient developed an immune thrombocytopenia
controlled by splenectomy. None of their donors had had a
documented AID.
Discussion
In this study, we show that about one in ten AA patients
will develop a concomitant AID during their lifetime,
which can appear at any time before and/or after the onset
of the AA. The frequency of a concomitant AID is higher in
older AA patients. Hence, more than 25% of AA patients
diagnosed after 50 years of age presented a concomitant
AID. The main type of concomitant AID appeared to be
either gastritis or thyroiditis. AA response to ATG wasTa
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similar in patients with or without AID, but AID response
to ATG was poor.
There are some particular features of the AID occurring
in AA patients. In contrast to the general population where
AID are more common in females [19], in AA patients,
AID were more frequently observed in males (15 out of 24,
62%). Interestingly, we did not observe cases of rheumatoid
arthritis and only one case of systemic lupus erythematosus.
HLA-DRB1*15 has been shown to be involved in the
development and the outcome of AA and other autoim-
mune disorders [20–23]. It seems unlikely that HLA-
DRB1*15 plays a relevant role in the appearance of
concomitant AID in AA patients.
Most cases of acquired AA can be considered as
autoimmune disorders characterized by T cell-mediated,
organ-specific destruction of bone marrow hematopoietic
cells. However, the usual trigger of this autoimmune
reaction remains unclear. In individual patients, the aberrant
immune response can sometimes be linked to a viral
infection or to drug or chemical exposure. There is much
less evidence for other mechanisms including the associa-
tion with other AID. In consideration of the high frequency
of a concomitant AID in AA patients, it is unlikely that
both diseases appear together just by chance. It, therefore,
raises the question of related pathophysiologic mechanisms.
In posthepatitis AA, which typically occurs in young,
Fig. 1 Age repartition at diagno-
sis of AAwithout AID (a)
and with AID (b). The data are
presented in percentage of the
whole group. Patients are divided
into three age groups: <20,
20–50, and >50 years (P<0.001).
AA patients without AID are
significantly younger than AA
patients with a concomitant AID.
c Cumulative incidence of AA
and the concomitant AID
according to the age at diagnosis
of each disease. The slope of the
curve is different for both dis-
eases. In AA, the cumulative
incidence increases mainly dur-
ing the first three decades of age,
whereas in concomitant AID, the
cumulative incidence increases
predominantly after the fifth
decade of life
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healthy males with self-limited but severe liver inflamma-
tion, a common inciting infectious cause could be involved
[24]. Indeed, in hepatitis-associated AA, similar skewed T
cell repertoires have been detected in the liver and in the
peripheral blood lymphocytes, suggesting that a similar
antigen-driven pathogenic mechanism is involved for both
diseases [25]. This might be different for the concomitant
AIDs. Here, there are arguments in favor of distinct
mechanisms: the different age repartition of AA patients
with and without concomitant AID; the nonresponse of the
AID in patients responding to immunosuppressive treat-
ment for the AA and the fact that AA is a T cell-mediated
AID, while in many of the concomitant AID, autoanti-
bodies are involved. Common genetic backgrounds, addi-
tional immunogenetic, environmental, or hormonal factors
may be responsible for the formation of subsets of AID
clustering [26]. The AIDs occurring after successful
allogeneic HSCT with full donor chimerism do not
probably belong to the same category. Late secondary
autoimmune-like phenomena have been described after
allogeneic HSCT as a possible consequence of skewed
immune reconstitution [27].
The older age of our AA patients with concomitant
AID suggests that immunosenescence could play a role.
Recent studies in healthy octogenarian patients indicate
that the immune system, instead of suffering a general-
ized deterioration, undergoes a remodeling/readjustment
of its major functions. Two divergent phenomena may
coexist in immunosenescence: a decrease in the capacity
of immune response and, simultaneously, autoantibody
production [28].
Our study has limitations arising mainly from its
retrospective, single-center character and the lack of a
control population. There is a relatively small number of
patients at risk; however, considering that AA is a rare
disease, this is the first and largest study reporting on the
frequency of concomitant AID in AA patients followed up
systematically over a long period of time. The advantage of
a single-center study is the homogeneity of therapeutical
approaches and the consistent follow-up. At last control,
80% of the long-term survivors had a follow-up of more
than 7 years.
In conclusion, in this study, we show that the
development of a concomitant AID is frequent, partic-
ularly in older AA patients. The AID may appear at any
time before or after the AA, and the outcome of the AA
is not impaired by the concomitant AID, but the AID
does not usually respond to the immunosuppression
applied for the AA. The difference in response to ATG
therapy between AA and AID suggests independent
underlying immune mechanisms. Alternatively, one of
these diseases could be the trigger for a second immune
dysregulation.
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